Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

RAD 502 can halt tumour progression and prolong survival

Monday, February 5, 2024 1 min read
Key Takeaway: RAD 502 has demonstrated the ability to halt tumor progression and extend patient survival, according to recent clinical updates. The treatment is currently being evaluated in ongoing studies, with positive outcomes reported. This advancement highlights the potential of RAD 502 in improving cancer treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD 502 shows promise in halting tumor progression.
  • The treatment may prolong survival for patients.
  • Positive clinical updates indicate effective results.

Full Press Release Details

• Announcements
• Price Sensitive
• February 5, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• June 27, 2025
• Announcements
• February 9, 2024
• Announcements
• April 15, 2024
• Announcements
• August 21, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD 502?

RAD 502 is a treatment being evaluated for its ability to halt tumor progression.

How does RAD 502 affect survival rates?

RAD 502 has shown potential to prolong survival for patients in clinical studies.

What are the latest updates on RAD 502?

Recent clinical updates indicate positive results for RAD 502 in cancer treatment.

Who is developing RAD 502?

RAD 502 is being developed by Radiopharm Theranostics.

Tags: RADX Viatris Investor Conferences Healthcare RAD 502 tumor progression survival clinical updates Radiopharm Theranostics
Last updated: Feb 5, 2024